Procept company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

procept.com

About Procept

Procept is a premier provider of professional training programs specializing in Project Management, Business Analysis, IT Service Management, and Business Continuity Management - offering participants intensive instruction at the accreditation level. Our consulting division offers strategic consulting services to help your organization improve its maturity in our specialization areas

Procept Headquarter Location

1234 Kingston Rd. Suite 125

Toronto, Ontario, M1N 1P3,

Canada

(416) 693-5559,Toll-free (in US and Canada): 1-800-261-6861

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Procept Patents

Procept has filed 2 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/22/2016

7/10/2018

Catheters, Oncology, Experimental cancer drugs, Digestive system surgery, Medical terminology

Grant

Application Date

12/22/2016

Grant Date

7/10/2018

Title

Related Topics

Catheters, Oncology, Experimental cancer drugs, Digestive system surgery, Medical terminology

Status

Grant

Latest Procept News

PROCEPT secures $85m funding for image-guided surgical robotic system

Jul 1, 2021

The funds will be used for the global, commercial expansion of the AquaBeam robotic system AquaBeam robotic system uses single-use disposable handpiece to deliver Aquablation therapy. (Credit: Adam Radosavljevic from Pixabay) Surgical robotics company PROCEPT BioRobotics has secured $85m in Series G financing round for its AquaBeam robotic system. Led by Fidelity Management & Research Company, the financing round saw participation from new investor T. Rowe Price Associates and existing investors CPMG, Perceptive Advisors, Viking Global Investors and Duquesne Family Office. PROCEPT aims to use the proceeds from the round for the global and commercial expansion of the AquaBeam robotic system, an advanced and image-guided surgical robotic system developed for minimally invasive urologic surgery. Designed to deliver Aquablation therapy, the AquaBeam is claimed to be the first and only image-guided robotic therapy to treat benign prostatic hyperplasia (BPH). The AquaBeam robotic system uses single-use disposable handpiece to deliver Aquablation therapy, which will help provide predictable and reproducible outcomes. The Aquablation therapy integrates real-time, multi-dimensional imaging, automated robotics and heat-free waterjet ablation for targeted, controlled and immediate removal of prostate tissue. PROCEPT president and CEO Reza Zadno said: “Aquablation’s combination of safety and efficacy provide millions of men dealing with the disease of BPH an option that addresses the tradeoffs that exist with current treatment options. “We would like to welcome both Fidelity Management & Research Company LLC and T. Rowe Price Associates as shareholders to our company and thank our existing investors for their continued support. “We expect this capital will enable us to continue scaling our commercialization efforts to meet the global demand for Aquablation.”

Procept Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Procept Rank

  • Where is Procept's headquarters?

    Procept's headquarters is located at 1234 Kingston Rd., Toronto.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.